Pharma companies need to limit the presence of nitrosamines in human medicines: EMA
Patients should generally not be exposed to a lifetime risk of cancer exceeding 1 in 100,000 from nitrosamines in their medicines
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Home » European Medicines Agency
Browsing Tag
European Medicines Agency
Global regulators agree to three priority areas for cooperation on observational research during…
High-quality observational research is an important complement to evidence on safety, effectiveness of vaccines, treatments for…
First non-injectable treatment for severe low blood sugar levels
The medicine Baqsimi comes in a single-use dispenser which is ready to use and can be administered through the nose by caregivers
‘We are the first company in the world to get a patent for pooled stem cell technology’
Recently, Stempeutics observed the First Stem Cell Awareness Day in India with a public event to explain stem cell therapy options…